About CNS Therapeutics
CNS Therapeutics is a Healthcare company based in Saint Paul (United States) founded in 2007 by Richard Penn, and was acquired by Mallinckrodt Pharmaceuticals in September 2012. Biopharmaceuticals for spasticity and chronic pain are developed and supplied. CNS Therapeutics has raised $13.1 million across 3 funding rounds from investors including Mallinckrodt Pharmaceuticals, Thomas, McNerney & Partners and InterWest. Its focus areas include Life Sciences, Neurology, Drugs and Pain. Its legal entity is CNS THERAPEUTICS, INC. Its competitors include Flexion Therapeutics, Eliem Therapeutics and Zogenix; 3 of its 3 listed competitors have raised funding.
Company details
CNS Therapeutics was founded in 2007 in Saint Paul, United States, within the biopharmaceutical sector. Site-specific drugs for neurological disorders and chronic pain are developed, including Gablofen, a baclofen injection used to treat severe spasticity via intrathecal administration in pre-filled syringes and vials. Operations focus on pain management solutions. The company was acquired by Mallinckrodt in 2012, later integrated into Covidien, and subsequently into Medtronic.
- Headquarters Saint Paul, United States
- Founders Richard Penn
- Stage Acquired
- SectorsHealthcare
- Website cnstherapeutics.com
- Social LinkedIn
- Acquired by Mallinckrodt Pharmaceuticals (Sep 2012)
- Legal Name Cns Therapeutics, Inc.
- Total Equity Funding$13.1M (USD)
in 3 rounds
- Latest Funding Round$3.05M (USD), Series A
Dec 2012
- InvestorsMallinckrodt Pharmaceuticals
& 2 more
- Acquired byMallinckrodt Pharmaceuticals
(Sep 2012)
Funding Insights of CNS Therapeutics
CNS Therapeutics has successfully raised a total of $13.1M across 3 strategic funding rounds. The most recent funding activity was a Series A round of $3.05 million completed in December 2012. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $13.1M
- Total Rounds 3
- Last Round Series A — $3.05M
- First Round $7M
(Aug 2009)
- Investors Count 2
All 3 funding rounds of CNS Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2012 | $3.05M | Series A | – | – | – |
| Dec 2010 | $3.05M | Series A | – | – | – |
| Aug 2009 | $7M | Series A | – | Thomas, McNerney & Partners, InterWest Partners | – |
3 investors in total: 3 institutional.
Investors in CNS Therapeutics
CNS Therapeutics has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include Mallinckrodt Pharmaceuticals, Thomas, McNerney & Partners and InterWest.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
| tm-partners.com | ||||
Early-stage investing in IT and healthcare ventures. | interwest.com | |||
Specialty pharmaceutical products and diagnostic imaging agents are manufactured. | 1867 | mallinckrodt.com | St. Louis, United States |
Investor details for CNS Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of CNS Therapeutics
1 people are tracked at CNS Therapeutics (1 in leadership).
| Name | Role | Group |
|---|---|---|
Richard Penn | Co-Founder & CSO | Leadership |
Complete people profiles for CNS Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of CNS Therapeutics
4 dated milestones of CNS Therapeutics across 5 years, from founding to its latest funding, stage changes and deals.
- Founded CNS Therapeutics is founded.
- Funding First funding round of $7.0M.
- Exit Acquired by Mallinckrodt Pharmaceuticals.
- Funding Latest funding round, Series A, of $3.0M.
Competitors of CNS Therapeutics
CNS Therapeutics has 3 listed competitors in our database, 3 of them funded. They include Flexion Therapeutics, Eliem Therapeutics and Zogenix.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| flexiontherapeutics.com | 2007 | Woburn, United States | $62M | 692 | Developer of therapies for the treatment of musculoskeletal disorders | |
| eliemtx.com | 2018 | Boston, United States | $171.3M | 30 | Develops antibody-based treatments for autoimmune and inflammatory disorders. | |
| zogenix.com | 2006 | Emeryville, United States | $149.06M | 159 | Drug delivery systems for CNS disorders and pain are developed. |
Detailed competitors of CNS Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Pain Management
3 companies that operate in the same segment as CNS Therapeutics (Pain Management) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of therapies for the treatment of musculoskeletal disorders | 2007 | Woburn, Massachusetts, United States | USD 62 M | USD 85.55 M | 692 | |
Developer of therapeutics for pain relief and inflammatory diseases | 2004 | New York, New York, United States | USD 51 M | USD 4.33 M | 79 | |
GPCR ligand-based therapeutics for cardiovascular diseases and pain are developed. | 2007 | Philadelphia, Pennsylvania, United States | USD 203 M | USD 3.13 M | 35 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Cns Therapeutics
Complete news archive for CNS Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about CNS Therapeutics
CNS Therapeutics was founded in 2007 and raised its 1st funding round 2 years after it was founded.
CNS Therapeutics is headquartered in Saint Paul, United States. It is registered at Saint Paul, Minnesota, United States.
CNS Therapeutics is a funded company, having raised a total of $13.1M across 3 funding rounds to date. The company's 1st funding round was a Series A of $7M, raised on Aug 2009.
CNS Therapeutics was founded in 2007 in Saint Paul, United States, within the biopharmaceutical sector. Site-specific drugs for neurological disorders and chronic pain are developed, including Gablofen, a baclofen injection used to treat severe spasticity via intrathecal administration in pre-filled syringes and vials. Operations focus on pain management solutions. The company was acquired by Mallinckrodt in 2012, later integrated into Covidien, and subsequently into Medtronic.
CNS Therapeutics's top competitors include Flexion Therapeutics, Zogenix and Eliem Therapeutics.
CNS Therapeutics has 3 investors. Key investors include Mallinckrodt Pharmaceuticals, Thomas, McNerney & Partners, and InterWest.
CNS Therapeutics operates through Cns Therapeutics, Inc..
Yes. CNS Therapeutics was acquired by Mallinckrodt Pharmaceuticals in September 2012.